Effect of Clonidine on Imagery Scripts
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cocaine Abuse; Heroin Abuse
Intervention: Clonidine (Drug); placebo (Drug)
Phase: Phase 1
Status: Recruiting
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Kenzie Preston, Ph.D., Principal Investigator, Affiliation: NIDA IRP
Overall contact:
Kenzie Preston, Ph.D., Phone: 410-550-1639, Email: kpreston@intra.nida.nih.gov
Summary
This is a study of the effects of clonidine: how it affects responses to stress and to
things that remind people of drugs. Clonidine is being compared to placebo. Participants
listen to taped imagery scripts that invoke neutral, stress, and drug cues. Physiological
and psychological measures are collected.
Clinical Details
Study design: Basic Science, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Pharmacodynamics Study
Primary outcome: subjective ratings of drug craving and moodautonomic response (galvanic skin response [GSR]) heart rate and blood pressure endocrine responses (salivary cortisol and salivary α-amylase)
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- evidence of cocaine or heroin use
Exclusion Criteria:
- medical or psychiatric disorders that would contraindicate administration of
clonidine; medications with known interactions with clonidine
Locations and Contacts
Kenzie Preston, Ph.D., Phone: 410-550-1639, Email: kpreston@intra.nida.nih.gov
NIDA IRP, Baltimore, Maryland 21224, United States; Recruiting
Additional Information
Starting date: August 2005
Ending date: August 2010
Last updated: June 19, 2008
|
